Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129964 | 1.00 | ABCB11 (0.81) | ABCB11P2RX7 | |
| SCHEMBL4135561 | 0.93 | P2RX7 (0.70) | ABCB11P2RX7 | |
| SCHEMBL4126448 | 0.91 | P2RX7 (0.74) | ABCB11P2RX7 | |
| SCHEMBL4134364 | 0.91 | P2RX7 (0.70) | ABCB11P2RX7 | |
| SCHEMBL4134161 | 0.90 | P2RX7 (0.67) | ABCB11P2RX7 | |
| SCHEMBL4139163 | 0.90 | P2RX7 (0.67) | ABCB11P2RX7 | |
| SCHEMBL5145834 | 0.89 | P2RX7 (0.68) | ABCB11P2RX7 | |
| SCHEMBL6052984 | 0.88 | ABCB11 (0.64) | ABCB11P2RX7 | |
| SCHEMBL4134714 | 0.88 | P2RX7 (0.69) | ABCB11P2RX7 | |
| SCHEMBL4129284 | 0.88 | P2RX7 (0.69) | ABCB11P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176853-A1 | Adamantane derivatives | ALCARAZ LILIAN | 2009-07-09 | — | — | US | claimed |
| US-20080207577-A1 | Mixture of a P2X7 (purinergic) receptor antagonist, and a corticosteroid; 1-adamantylalkylamide derivatives with benzyl or pyridyl group; respiratory system disorders, chronic obstructive pulmonary disease; antiasthmatics; formoterol, budesonide; kits | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | claimed |
| US-20080139636-A1 | Adamantane derivatives | ASTRAZENECA AB. | 2008-06-12 | — | — | US | claimed |
| US-20070281931-A1 | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | claimed |
| EP-1862451-A1 | Adamantane derivatives for the treatment of inflammatory diseases | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | claimed |
| US-20070082930-A1 | Pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti-inflammatory drug | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | claimed |
| US-20070032465-A1 | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | claimed |
| US-20070010497-A1 | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | claimed |
| US-7132457-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | claimed |
| US-20060247257-A1 | Combination | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | US | claimed |
| US-6881754-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-19 | — | — | US | claimed |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | ASTRAZENECA AB | 2005-03-03 | — | — | US | claimed |
| EP-1242364-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | claimed |
| EP-1352895-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | claimed |
| EP-1352896-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | claimed |
| US-20130195919-A1 | INDUCED DENDRITIC CELL COMPOSITIONS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-08-01 | — | — | US | disclosed |
| US-20090176853-A1 | Adamantane derivatives | ALCARAZ LILIAN | 2009-07-09 | — | — | US | disclosed |
| EP-1352896-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1242364-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044170-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281931-A1 | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate | P2RX7, P2RY1, P2RX5 | ABCB11 184/4885P2RX7 1/4885 |
| US-20090176853-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | ABCB11 558/4885P2RX7 1692/4885 |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | HRH1, HRH2, HRH4 | ABCB11 2799/4885P2RX7 1020/4885 |
| US-20070010497-A1 | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine | P2RX7, P2RX5, P2RX2 | ABCB11 267/4885P2RX7 1/4885 |
| US-20070082930-A1 | Pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti-inflammatory drug | P2RX7, P2RX3, P2RX5 | ABCB11 159/4885P2RX7 1/4885 |
| US-20060247257-A1 | Combination | P2RX7, PCSK9, P2RX1 | ABCB11 317/4885P2RX7 1/4885 |
| US-20080207577-A1 | Mixture of a P2X7 (purinergic) receptor antagonist, and a corticosteroid; 1-adamantylalkylamide derivatives with benzyl or pyridyl group; respiratory system disorders, chronic obstructive pulmonary disease; antiasthmatics; formoterol, budesonide; kits | P2RY1, P2RX3, P2RX7 | ABCB11 342/4885P2RX7 3/4885 |
| US-20080139636-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | ABCB11 558/4885P2RX7 1692/4885 |
| US-20070032465-A1 | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha | P2RX7, P2RX1, P2RX5 | ABCB11 345/4885P2RX7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.